Cochrane · systematic review · CD004982
Treatment for superficial thrombophlebitis of the leg
Di Nisio, M, Wichers, IM, Middeldorp, S · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
25
current version
GRADE rated
16
No studies
9
Included studies
NR
No studies 9 · 36%Ungraded 0 · 0%Very low 0 · 0%Low 9 · 36%Moderate 7 · 28%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Fondaparinux compared to placebo for superficial thrombophlebitis of the leg
Population: people with ST of the leg
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Symptomatic VTE Ventilation‐perfusion scanning, helical computed tomography, pulmonary angiography, autopsy, ultrasonography, or venography Fondaparinux vs placebo | RR 0.15 [0.04, 0.5] | 1 study · 3002 participants | Moderate Downgraded: imprecision |
Major bleeding Fondaparinux vs placebo | RR 0.99 [0.06, 15.86] | 1 study · 2987 participants | Moderate Downgraded: imprecision |
Extension of ST Ultrasonography Fondaparinux vs placebo | RR 0.08 [0.03, 0.22] | 1 study · 3002 participants | Moderate Downgraded: imprecision |
Recurrence of ST Ultrasonography Fondaparinux vs placebo | RR 0.21 [0.08, 0.54] | 1 study · 3002 participants | Moderate Downgraded: imprecision |
Mortality Fondaparinux vs placebo | RR 2 [0.18, 22] | 1 study · 3002 participants | Moderate Downgraded: imprecision |
Minor bleeding Fondaparinux vs placebo | RR 1.49 [0.53, 4.17] | 1 study · 2987 participants | Moderate Downgraded: imprecision |
Adverse effects of treatment Fondaparinux vs placebo | RR 1.13 [0.78, 1.65] | 1 study · 2987 participants | Moderate Downgraded: imprecision |
Prophylactic LMWH versus placebo for superficial thrombophlebitis of the leg
Population: people with ST of the leg
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Symptomatic VTE Prophylactic LMWH vs placebo | RR 1.22 [0.38, 3.89] | 1 study · 222 participants | Low Downgraded: risk of bias, imprecision |
Major bleeding Prophylactic LMWH vs placebo | no estimate extracted | 1 study · 222 participants | Low Downgraded: risk of bias, imprecision |
Extension or recurrence (or both) of ST Prophylactic LMWH vs placebo | RR 0.44 [0.26, 0.74] | 1 study · 222 participants | Low Downgraded: risk of bias, imprecision |
Mortality Prophylactic LMWH vs placebo | no estimate extracted | NR | No studies |
Minor bleeding Prophylactic LMWH vs placebo | no estimate extracted | NR | No studies |
Adverse effects of treatment Prophylactic LMWH vs placebo | no estimate extracted | NR | No studies |
Therapeutic LMWH versus placebo for superficial thrombophlebitis of the leg
Population: people with ST of the leg
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Symptomatic VTE Therapeutic LMWH vs placebo | RR 0.85 [0.23, 3.06] | 1 study · 218 participants | Low Downgraded: risk of bias, imprecision |
Major bleeding Therapeutic LMWH vs placebo | no estimate extracted | 1 study · 218 participants | Low Downgraded: risk of bias, imprecision |
Extension or recurrence (or both) of ST Therapeutic LMWH vs placebo | RR 0.46 [0.27, 0.77] | 1 study · 218 participants | Low Downgraded: risk of bias, imprecision |
Mortality Therapeutic LMWH vs placebo | no estimate extracted | NR | No studies |
Minor bleeding Therapeutic LMWH vs placebo | no estimate extracted | NR | No studies |
Adverse effects of treatment Therapeutic LMWH vs placebo | no estimate extracted | NR | No studies |
NSAIDs versus placebo for superficial thrombophlebitis of the leg
Population: people with superficial thrombophlebitis of the leg
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Symptomatic VTE NSAIDs vs placebo | RR 0.91 [0.25, 3.28] | 1 study · 211 participants | Low Downgraded: risk of bias, imprecision |
Major bleeding NSAIDs vs placebo | no estimate extracted | 1 study · 211 participants | Low Downgraded: risk of bias, imprecision |
Extension or recurrence (or both) of ST NSAIDs vs placebo | RR 0.46 [0.27, 0.78] | 1 study · 211 participants | Low Downgraded: risk of bias, imprecision |
Mortality NSAIDs vs placebo | no estimate extracted | NR | No studies |
Minor bleeding NSAIDs vs placebo | no estimate extracted | NR | No studies |
Adverse effects of treatment NSAIDs vs placebo | no estimate extracted | NR | No studies |